Product ID: SQMIG35H2201
Report ID:
SQMIG35H2201 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
96 |
Figures:
76
In October 2023, FOXO Technologies Inc., a leader in the field of commercializing epigenetic biomarker technology, has announced plans for a new subscription-based, direct-to-consumer product offering that will provide personalized health and wellness recommendations. In connection with this, the Company also announced it has formed a collaboration with KR8.ai Inc. and secured an exclusive license to KR8’s AI-based software to support the development and commercial launch of the new health and wellness offering.
In October 2023, Zenith Epigenetics Ltd., a global leader in epigenetics, announced that it has entered into an agreement with Cencora for accelerating the commercialization of Zenith Epigenetics' ZEN-3694 program (an advanced epigenetic approach for advancing the efficacy of cancer treatment of currently marketed drugs). Existing partners and collaborators include Pfizer, Merck, BMS, Eli Lilly, Astellas, GSK, and Syndax and is supported by numerous collaborators and partners such as National Cancer Institute, National Institute of Health, Dana Farber-Harvard, Yale, UCSF, Memorial Sloan Kettering, and MD Anderson.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35H2201